{
    "hands_on_practices": [
        {
            "introduction": "Understanding immunodeficiency requires moving beyond simple descriptions to quantitative models. This first practice invites you to build a simple but powerful model that treats infection as a dynamic tug-of-war between pathogen replication, at rate $r$, and immune clearance, at rate $c$. By deriving the critical Absolute Neutrophil Count ($\\text{ANC}^*$) below which an infection can take hold, you will gain a deeper, mathematical appreciation for why neutropenia is a major risk factor for opportunistic infections. ",
            "id": "4640893",
            "problem": "A patient receiving cytotoxic chemotherapy develops profound neutropenia and is exposed to an opportunistic bacterial pathogen. Consider the early-phase pathogen population, where the pathogen burden, denoted by $B(t)$, changes according to a per-capita replication rate $r$ and a per-capita immune clearance rate $c$. In this early phase, assume that $r$ and $c$ are constants over the timescale of interest and that the infection expands when $r>c$. In neutropenic hosts, innate clearance is dominated by neutrophils; assume the clearance rate is proportional to the Absolute Neutrophil Count (ANC), so that $c \\propto \\text{ANC}$. Let the proportionality be $c = k \\,\\text{ANC}$, where $k$ is a constant.\n\nStarting from the definition of per-capita growth and clearance in population dynamics, construct the threshold model that determines whether the infection expands or contracts, and derive a general expression for the critical Absolute Neutrophil Count (denote it $\\text{ANC}^{\\ast}$) at which the infection neither expands nor contracts. Then, using the following empirically estimated parameters for an opportunistic bacterium in vivo: replication rate $r = 0.20\\,\\text{day}^{-1}$ and neutrophil-mediated per-cell clearance coefficient $k = 4.0 \\times 10^{-4}\\,\\text{day}^{-1}\\,(\\text{cell}\\,\\mu\\text{L}^{-1})^{-1}$, compute the numerical value of $\\text{ANC}^{\\ast}$. Express your final answer in cells per microliter. No rounding is required unless it is unavoidable; if you choose to round, report your answer to three significant figures.",
            "solution": "The problem asks for the derivation of a threshold model for pathogen expansion and the calculation of a critical Absolute Neutrophil Count ($\\text{ANC}^{\\ast}$).\n\nFirst, the validation of the problem statement is performed.\n\n**Step 1: Extract Givens**\n- Pathogen burden is denoted by $B(t)$.\n- The per-capita replication rate is a constant, $r$.\n- The per-capita immune clearance rate is a constant, $c$.\n- Infection expands when $r > c$.\n- The clearance rate $c$ is proportional to the Absolute Neutrophil Count ($\\text{ANC}$), given by the relation $c = k \\,\\text{ANC}$.\n- $k$ is the neutrophil-mediated per-cell clearance coefficient.\n- $\\text{ANC}^{\\ast}$ is the critical Absolute Neutrophil Count at which the infection neither expands nor contracts.\n- The value of the replication rate is $r = 0.20\\,\\text{day}^{-1}$.\n- The value of the clearance coefficient is $k = 4.0 \\times 10^{-4}\\,\\text{day}^{-1}\\,(\\text{cell}\\,\\mu\\text{L}^{-1})^{-1}$.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, employing a standard Malthusian growth model modified with a linear clearance term. This is a common and valid simplification in population dynamics and mathematical epidemiology. The parameters are physically realistic, and their units are consistent. The relation $c = k \\,\\text{ANC}$ implies that the rate of clearance of pathogens is proportional to the concentration of neutrophils, which is a plausible assumption for a first-order model of innate immune response. The problem is well-posed, with all necessary information provided to derive the requested quantities. It is objective and free of any speculative or non-scientific claims.\n\n**Step 3: Verdict and Action**\nThe problem is deemed valid. A solution will be constructed.\n\nThe dynamics of the pathogen population, $B(t)$, can be described by a differential equation. The rate of change of the population, $\\frac{dB}{dt}$, is the difference between the total rate of replication and the total rate of clearance.\nThe total replication rate is the per-capita rate $r$ multiplied by the population size $B(t)$, which is $rB(t)$.\nThe total clearance rate is the per-capita rate $c$ multiplied by the population size $B(t)$, which is $cB(t)$.\nTherefore, the differential equation governing the pathogen burden is:\n$$\n\\frac{dB(t)}{dt} = rB(t) - cB(t) = (r - c)B(t)\n$$\nThis is the fundamental threshold model. The sign of the net growth rate, $(r-c)$, determines the fate of the infection.\n- If $r - c > 0$, or $r > c$, then $\\frac{dB}{dt} > 0$ (assuming $B>0$), and the infection expands.\n- If $r - c < 0$, or $r < c$, then $\\frac{dB}{dt} < 0$, and the infection contracts.\n- If $r - c = 0$, or $r = c$, then $\\frac{dB}{dt} = 0$, and the pathogen burden remains constant. This is the critical threshold condition where the infection neither expands nor contracts.\n\nThe problem states that the per-capita clearance rate $c$ is a function of the Absolute Neutrophil Count, $\\text{ANC}$, given by the expression:\n$$\nc = k \\, \\text{ANC}\n$$\nwhere $k$ is a constant of proportionality.\n\nThe critical Absolute Neutrophil Count, denoted $\\text{ANC}^{\\ast}$, is the value of $\\text{ANC}$ for which the system is at the threshold, i.e., $r = c$. We can find the expression for $\\text{ANC}^{\\ast}$ by substituting the relationship for $c$ into the threshold condition:\n$$\nr = k \\, \\text{ANC}^{\\ast}\n$$\nSolving this equation for $\\text{ANC}^{\\ast}$ yields the general expression for the critical neutrophil count:\n$$\n\\text{ANC}^{\\ast} = \\frac{r}{k}\n$$\nThis expression defines the minimum neutrophil count required to control the infection (i.e., prevent its net growth).\n\nNow, we compute the numerical value of $\\text{ANC}^{\\ast}$ using the provided parameters:\n- $r = 0.20\\,\\text{day}^{-1}$\n- $k = 4.0 \\times 10^{-4}\\,\\text{day}^{-1}\\,(\\text{cell}\\,\\mu\\text{L}^{-1})^{-1}$\n\nSubstituting these values into the derived expression:\n$$\n\\text{ANC}^{\\ast} = \\frac{0.20\\,\\text{day}^{-1}}{4.0 \\times 10^{-4}\\,\\text{day}^{-1}\\,(\\text{cell}\\,\\mu\\text{L}^{-1})^{-1}}\n$$\nThe units of $\\text{day}^{-1}$ in the numerator and denominator cancel. The unit of $(\\text{cell}\\,\\mu\\text{L}^{-1})^{-1}$ in the denominator becomes $\\text{cell}\\,\\mu\\text{L}^{-1}$ in the final result, which is the correct unit for a cell concentration.\nPerforming the arithmetic:\n$$\n\\text{ANC}^{\\ast} = \\frac{0.20}{4.0 \\times 10^{-4}} = \\frac{2.0 \\times 10^{-1}}{4.0 \\times 10^{-4}} = \\frac{2.0}{4.0} \\times 10^{-1 - (-4)} = 0.5 \\times 10^{3} = 500\n$$\nThe numerical value is exact, so no rounding is necessary. The critical Absolute Neutrophil Count is $500\\,\\text{cells}\\,\\mu\\text{L}^{-1}$. This value is clinically significant, as an ANC below $500\\,\\text{cells}\\,\\mu\\text{L}^{-1}$ defines severe neutropenia, a condition associated with a high risk of infection.",
            "answer": "$$\n\\boxed{500}\n$$"
        },
        {
            "introduction": "Diagnosing infections in immunocompromised patients often involves uncertainty, so a key skill is knowing how to revise clinical suspicion based on new evidence. This exercise will guide you through the application of Bayesian reasoning, using a diagnostic test's likelihood ratio to update a pre-test probability of infection into a more definitive post-test probability. This process is a cornerstone of modern, evidence-based diagnostics and critical for timely intervention. ",
            "id": "4640958",
            "problem": "An immunocompromised host with prolonged neutropenia due to acute myeloid leukemia presents with fever and pulmonary nodules on imaging. Serum galactomannan is positive. In this clinical context, practitioners had estimated a pretest probability of invasive aspergillosis of $0.20$. A meta-analysis reports the positive likelihood ratio (LR) for a positive galactomannan as $LR_{+}=7$ in similar hosts. Starting from the definitions underpinning Bayes' theorem for diagnostic tests and the meaning of the likelihood ratio in terms of how test results update odds, derive the posttest probability of invasive aspergillosis after a positive galactomannan in this patient. Express your final answer as a single decimal probability rounded to four significant figures, with no units. Finally, provide a brief interpretation of what this posterior probability implies for clinical decision-making in an immunocompromised host. Do not use any percentage sign.",
            "solution": "The problem is valid as it is scientifically grounded in clinical epidemiology, well-posed, and provides all necessary information for a unique solution using Bayes' theorem.\n\nLet $D$ be the event that the patient has invasive aspergillosis, and let $T^+$ be the event of a positive serum galactomannan test. We are given the following information:\n1.  The pretest probability of the disease, $P(D) = 0.20$.\n2.  The positive likelihood ratio for the test, $LR_{+} = 7$.\n\nOur goal is to calculate the posttest probability of the disease given a positive test result, which is denoted as $P(D|T^+)$.\n\nWe begin by relating probability to odds. The odds of an event $A$ are defined as the ratio of the probability of the event occurring to the probability of the event not occurring:\n$$ \\text{Odds}(A) = \\frac{P(A)}{1 - P(A)} $$\nUsing this definition, we can calculate the pretest odds of invasive aspergillosis:\n$$ \\text{Pretest Odds} = \\text{Odds}(D) = \\frac{P(D)}{1 - P(D)} = \\frac{0.20}{1 - 0.20} = \\frac{0.20}{0.80} = 0.25 $$\n\nThe likelihood ratio of a positive test, $LR_{+}$, is defined as the ratio of the probability of a positive test in a patient with the disease (sensitivity) to the probability of a positive test in a patient without the disease ($1-$specificity).\n$$ LR_{+} = \\frac{P(T^+|D)}{P(T^+|D^c)} $$\nwhere $D^c$ is the event that the patient does not have the disease.\n\nThe relationship between pretest odds, posttest odds, and the likelihood ratio is derived from Bayes' theorem. Bayes' theorem states:\n$$ P(D|T^+) = \\frac{P(T^+|D) P(D)}{P(T^+)} $$\nSimilarly, for the complementary event $D^c$:\n$$ P(D^c|T^+) = \\frac{P(T^+|D^c) P(D^c)}{P(T^+)} $$\nThe posttest odds are the ratio of these two posterior probabilities:\n$$ \\text{Posttest Odds} = \\frac{P(D|T^+)}{P(D^c|T^+)} = \\frac{P(T^+|D) P(D) / P(T^+)}{P(T^+|D^c) P(D^c) / P(T^+)} $$\nThe term $P(T^+)$ cancels, yielding:\n$$ \\text{Posttest Odds} = \\frac{P(T^+|D)}{P(T^+|D^c)} \\times \\frac{P(D)}{P(D^c)} $$\nRecognizing the terms on the right-hand side, we arrive at the odds form of Bayes' theorem:\n$$ \\text{Posttest Odds} = LR_{+} \\times \\text{Pretest Odds} $$\nWe are given $LR_{+} = 7$ and we calculated the pretest odds to be $0.25$. Therefore, we can find the posttest odds:\n$$ \\text{Posttest Odds} = 7 \\times 0.25 = 1.75 $$\n\nFinally, we convert the posttest odds back into a probability. If $\\text{Odds}(A) = O$, then the probability $P(A)$ is given by:\n$$ P(A) = \\frac{O}{1 + O} $$\nApplying this to our posttest odds:\n$$ P(D|T^+) = \\frac{\\text{Posttest Odds}}{1 + \\text{Posttest Odds}} = \\frac{1.75}{1 + 1.75} = \\frac{1.75}{2.75} $$\nTo perform the calculation exactly, we can use fractions: $1.75 = \\frac{7}{4}$ and $2.75 = \\frac{11}{4}$.\n$$ P(D|T^+) = \\frac{7/4}{11/4} = \\frac{7}{11} $$\nAs a decimal, this is approximately $0.636363...$. The problem requires the answer to be rounded to four significant figures.\n$$ P(D|T^+) \\approx 0.6364 $$\n\nThe brief interpretation of this posterior probability for clinical decision-making is as follows:\nThe positive serum galactomannan test significantly increased the likelihood of invasive aspergillosis in this high-risk patient, raising the probability from a pretest value of $0.20$ (a suspicion) to a posttest value of approximately $0.64$ (a high probability). In the context of a life-threatening infection in an immunocompromised host, a posterior probability of this magnitude typically crosses the \"treatment threshold.\" It provides strong evidence to justify the initiation of empiric antifungal therapy (e.g., with a mold-active azole like voriconazole) immediately, rather than waiting for more definitive, and often invasive, diagnostic procedures like a lung biopsy. This change in probability directly informs a shift in clinical management from observation or further low-yield testing to active, targeted intervention.",
            "answer": "$$ \\boxed{0.6364} $$"
        },
        {
            "introduction": "Preventing infections (prophylaxis) is a key strategy in managing immunocompromised patients, but how do we measure its effectiveness across a population? This practice introduces two fundamental metrics from clinical epidemiology: the Absolute Risk Reduction (ARR) and the Number-Needed-to-Treat (NNT). By calculating these values from hypothetical trial data, you will learn to translate a relative risk reduction into a practical measure of a drug's real-world impact, which is essential for making informed clinical and public health decisions. ",
            "id": "4640900",
            "problem": "A cohort of adult patients with acute lymphoblastic leukemia receiving induction chemotherapy is at high risk for Pneumocystis jirovecii pneumonia (PJP). Without prophylaxis, the observed $12$-month cumulative incidence (risk) of a first PJP episode is $0.12$. A randomized trial in a clinically similar population shows that daily trimethoprim-sulfamethoxazole (TMP–SMX) prophylaxis confers a constant relative risk reduction of $0.85$ for PJP over the same $12$-month horizon. Assume adherence is sufficient that this relative risk reduction applies uniformly to the $12$-month risk.\n\nUsing only core definitions of risk, relative risk, and relative risk reduction, determine the absolute risk reduction (ARR) and the number-needed-to-treat (NNT) for TMP–SMX prophylaxis for preventing at least one PJP episode over $12$ months in this population.\n\nInstructions:\n- Treat the $12$-month cumulative incidence without prophylaxis as the baseline risk.\n- Express the ARR as a decimal fraction (do not use a percent sign).\n- Express the NNT as a dimensionless quantity using the conventional definition $NNT = 1/ARR$ without applying a ceiling function.\n- Round both values to three significant figures.\n- Report your answers in the order (ARR, NNT).",
            "solution": "The problem requires the calculation of the absolute risk reduction ($ARR$) and the number-needed-to-treat ($NNT$) for a prophylactic intervention based on provided epidemiological data. The problem is valid as it is scientifically sound, well-posed with sufficient and consistent information, and uses objective, standard terminology.\n\nFirst, we identify and define the variables from the problem statement.\nLet $R_c$ be the risk, or $12$-month cumulative incidence, of a first *Pneumocystis jirovecii* pneumonia (PJP) episode in the control group (without prophylaxis).\nLet $R_t$ be the risk of PJP in the treatment group (with trimethoprim-sulfamethoxazole prophylaxis).\n\nAccording to the problem, the baseline risk in the control group is:\n$$R_c = 0.12$$\n\nThe relative risk reduction ($RRR$) is given as:\n$$RRR = 0.85$$\n\nThe core definitions requested are as follows:\nThe relative risk reduction is the proportional decrease in risk in the treated group compared to the control group, defined as:\n$$RRR = \\frac{R_c - R_t}{R_c}$$\n\nThe absolute risk reduction ($ARR$) is the absolute difference in risk between the two groups:\n$$ARR = R_c - R_t$$\n\nThe number-needed-to-treat ($NNT$) is the reciprocal of the $ARR$:\n$$NNT = \\frac{1}{ARR}$$\n\nTo find the $ARR$, we can establish a direct relationship between $ARR$, $R_c$, and $RRR$. From the definition of $RRR$, we can write:\n$$RRR \\times R_c = R_c - R_t$$\nSince the right-hand side is the definition of $ARR$, we have:\n$$ARR = R_c \\times RRR$$\n\nSubstituting the given values into this equation:\n$$ARR = 0.12 \\times 0.85$$\n$$ARR = 0.102$$\nThe problem asks for this value to be rounded to three significant figures. The value $0.102$ consists of the significant figures $1$, $0$, and $2$, so it is already expressed to the correct precision.\n\nNext, we calculate the $NNT$ using the value of $ARR$ just determined. The problem specifies to use the formula $NNT = 1/ARR$ without applying a ceiling function.\n$$NNT = \\frac{1}{0.102}$$\n$$NNT \\approx 9.80392156...$$\nThis value must also be rounded to three significant figures. The first three significant digits are $9$, $8$, and $0$. The fourth significant digit is $3$, which is less than $5$, so we round down.\n$$NNT \\approx 9.80$$\n\nThe final answers for $ARR$ and $NNT$, rounded to three significant figures, are $0.102$ and $9.80$, respectively. The problem requires the answer to be reported in the order ($ARR$, $NNT$).",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.102 & 9.80 \\end{pmatrix}}$$"
        }
    ]
}